Market Overview

GlaxoSmithKline, Kinder Morgan And Others Insiders Have Been Buying

Related GSK
Markets Reverse Early Morning Losses; Still Lower On The Day
Benzinga's M&A Chatter for Wednesday August 27, 2014
Bayer Buys Merck Consumer Care Unit (Fox Business)

Pullbacks and sell-offs provide a perfect opportunity for investors who have faith in a company to snap up shares. Here are some stocks that have seen insider buying recently.

Aircastle

Japanese trading company Marubeni Corp. has been scooping up batches of Aircastle (NYSE: AYR) shares since last August. That included 174,000 of them in the past two weeks, for more than $3.1 million. The jet-rental company recently has been a rumored takeover target.

The market capitalization is about $1.5 billion and the long-term earnings per share (EPS) growth forecast is more than 29 percent. The dividend yield is about 4.4 percent. Shares have traded mostly between $18 and $19 since the end of October. Over the past six months, the stock has underperformed competitors Air Lease and Fly Leasing.

Atlas Pipeline Partners

The chairman and the vice chairman each bought 10,000 shares of Atlas Pipeline Partners (NYSE: APL) last week. Altogether that was worth almost $600,000. Shares of this natural gas company dropped following the fourth-quarter earnings release and subsequent analyst downgrades.

The market capitalization is now more than $2 billion and the long-term EPS growth forecast is almost 38 percent. The distribution yield is about 7.5 percent. Shares are more than five percent lower than at the beginning of the month. The stock has underperformed the broader market over the past six months.

See also: Carlos Slim Doubles His Stake In The New York Times

GlaxoSmithKline

Beneficial owners and former beneficial owners bought more than 521,000 shares in three transactions this month. That was worth more than $6.6 million. GlaxoSmithKline (NYSE: GSK), a U.K. pharmaceutical company, has been lobbying for increased regulation of e-cigarettes.

Its market cap is more than $133 billion, and the company offers a dividend yield around 5.3 percent. The return on equity is more than 114 percent. Shares reached a new multiyear high last week. Yet the stock has underperformed competitors Merck, Novartis and Pfizer over the past six months.

Kinder Morgan

The CEO purchased almost $3.3 million worth of Kinder Morgan (NYSE: KMI) shares last week. That was 100,000 shares. Earlier this month, this Houston-based energy transport company was sued by an investor for alleged improper distributions.

Kinder Morgan has a market cap of more than $34 billion, and its price-to-earnings (P/E) ratio is less than the industry average. The share price has retreated almost three percent in February. Over the past six months, the stock has underperformed the likes of Enterprise Products Partners and Williams Companies.

Opko Health

The chairman continues to buy batches of shares periodically, as he has done for more than a year. He picked up about 75,000 Opko Health (NYSE: OPK) shares last week for a total price of around $648,000. He has bought more than 689,000 shares so far this month.

This Miami-based health care company has a market cap of more than $3 billion, and short interest is more than 21 percent of its float. The share price is up more than 12 percent in the past two weeks. Over the past six months, the stock has underperformed the broader markets and competitor Allergan.

See also: Hewlett-Packard CEO Meg Whitman Ready For 'New World' Of Tech

SM Energy

The president and the general counsel acquired a combined 4,500 SM Energy (NYSE: SM) shares last week for more than $324,000. A disappointing Eagle Ford resource update and lower-than-expected quarterly earnings resulted in analyst downgrades last week.

The market cap of this Denver-based company is less than $5 billion. Its dividend yield is only about 0.1 percent, but the long-term EPS growth forecast is more than 46 percent. The share price lost more than 16 percent last week. But over the past six months, the stock has outperformed larger competitor Chesapeake Energy.

At the time of this writing, the author had no position in the mentioned equities.

Keep up with all the latest breaking news and trading ideas by following us on Twitter.

Posted-In: air lease Aircastle Allergan Atlas Pipeline Partners chesapeake energy Enterprise Products PartnersNews Insider Trades Best of Benzinga

 

Related Articles (APL + AYR)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters